Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DNA methylation landscapes of human fetal development

ABSTRACT: Here we assessed the genome-scale DNA methylation of 472,703 autosomal CpG sites in 4 tissues (muscle, amnion, pancreas and adrenal glands) on 3 time-points (9, 18 and 22 weeks) using the Illumina 450k array. We identified 52,134 CpG sites with dynamic DNA methylation during fetal development (gain or loss >20% from 9 to 22 weeks), where the period between 9 and 18 weeks was most dynamic. Loss in DNA methylation (25,579 CpGs), displayed clear tissue-specific patterns near genes enriched for a role in tissue-specific processes. Gain in DNA methylation (26,555 CpGs) occurred often near genes involved in (tissue-specific) developmental processes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE56515 | GEO | 2015/09/22

SECONDARY ACCESSION(S): PRJNA243583

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

DNA methylation landscapes of human fetal development

Project description:Here we assessed the genome-scale DNA methylation of 472,703 autosomal CpG sites in 4 tissues (muscle, amnion, pancreas and adrenal glands) on 3 time-points (9, 18 and 22 weeks) using the Illumina 450k array. We identified 52,134 CpG sites with dynamic DNA methylation during fetal development (gain or loss >20% from 9 to 22 weeks), where the period between 9 and 18 weeks was most dynamic. Loss in DNA methylation (25,579 CpGs), displayed clear tissue-specific patterns near genes enriched for a role in tissue-specific processes. Gain in DNA methylation (26,555 CpGs) occurred often near genes involved in (tissue-specific) developmental processes. Comparison of DNA methylation of four fetal human tissues on three time points of gestation: 9, 18 and 22 weeks of gestation.

2015-09-22 | E-GEOD-56515 | biostudies-arrayexpress

Characterization of genome-methylome interactions in 22 nuclear pedigrees

Project description:In this study, we investigated the interaction between CpG methylation and genetic polymorphisms by taking the advantage of the family structure in 22 nuclear pedigrees. We have identified CpG sites that exhibit heritable methylation patterns, among which the majority are SNPs ditrectly disrupting CpG dinucleotides. We also identified 27.2% of the heritable non-SNP CpGs were associated with cis-regulatory SNPs. Additionally, we have identified hundreds of CpG clusters whose the degree of DNA methylation variation is associated with genetic polymorphism. Investigate the influence of genetic variances on blood DNA methylation patterns in the human genome of 96 subjects from 22 pedigrees by using different approaches, including mid-parent offspring analysis (MPO), methylation quantitative trait loci (mQTL) analysis and allele-specific DNA methylation (ASM) Raw data not provided since the files contain genetic information of the human subject that should be protected.

2013-06-20 | E-GEOD-47614 | biostudies-arrayexpress

Characterization of genome-methylome interactions in 22 nuclear pedigrees

2013-06-20 | GSE47614 | GEO

Recurrent chromosomal and epigenetic alterations in oral squamous cell carcinoma and its putative premalignant condition oral lichen planus

Project description:Genome wide DNA methylation profiling of OSCC tissue samples, oral lichen planus tissue samples and normal controls. The Illumina Infinium 450k Human DNA methylation Beadchip was used to obtain DNA methylation profiles across approximately 480,000 CpGs. Samples included 15 OSCC, 8 lichen planus and 18 control samples.

2019-04-17 | GSE123781 | GEO

Enhanced Reduced Representation Bisulfite Sequencing of BPH and control samples

Project description:We investigated the epigenetic landscape of benign prostatic hyperplasia (BPH) by defining the DNA methylation profile of 18 BPH samples and 5 controls from normal transitional zone. We identified 92,046 hypermethylated CpG and 10,117 hypomethylated CpG across different genomic regions in BPH, and hypermethylation was the dominant signal across all genomic regions, even when controlling for bias of CpG-rich loci. We defined a methylation signature for BPH that included 696 differentially methylated CpGs in promoter regions.

2020-03-18 | GSE123111 | GEO

Epigenome analysis of schwannomas

Project description:Genome-wide DNA methylation profiling of 22 schwannomas belonging to three different genotypes (NF2-mutant, SOX10-mutant, and HTRA1-fused). The Illumina Infinium EPIC 850k Human DNA Methylation Beadchip was used to obtain DNA methylation profiles across approximately 850,000 CpG sites of genomic DNA extracted from formalin-fixed, paraffin-embedded tumor tissue of 22 schwannomas.

2023-07-13 | GSE197094 | GEO

Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer

2013-06-15 | GSE40055 | GEO

Mapping of variable DNA methylation across multiple cell types defines a dynamic regulatory landscape of the human genome

Project description:DNA methylation is an important epigenetic modification involved in many biological processes and diseases. Many studies have mapped DNA methylation changes associated with embryogenesis, cell differentiation and cancer at a genome-wide scale. Our understanding of genome-wide DNA methylation changes in a developmental or disease-related context has been steadily growing. However, the investigation of which CpGs are variably methylated in different normal cell or tissue types is still limited. Here we present an in-depth analysis of 54 single-CpG-resolution DNA methylomes of normal human cell types by integrating high-throughput sequencing-based methylation data. We find that the percentage of unmethylated CpGs is relatively fixed regardless of cell type. However, which CpGs are unmethylated is cell-type specific. We categorize the 26 million human autosomal CpGs based on their methylation levels across multiple cell types to identify variably methylated CpGs. Among all the autosomal CpGs, 22.6% exhibit variable DNA methylation across cell types included in our study. These variably methylated CpGs form 66 thousand variably methylated regions (VMRs), encompassing 11% of the genome. By integrating a multitude of genomic data, we found that VMRs enrich for histone modifications indicative of enhancers, suggesting their role as regulatory elements marking cell type specificity. VMRs enrich for transcription factor binding sites in a tissue-dependent manner. Importantly, they enrich for GWAS variants, suggesting VMRs could potentially be implicated in disease and complex traits. Taken together, our results highlight the link among CpG methylation variation, genetic variation and disease risk in a tissue-specific manner for many human cell types. Processed data includes new Samples and 75 Samples from GSE16368 and 2 Samples from GSE51565.

2016-04-06 | E-GEOD-69894 | biostudies-arrayexpress

Epigenetic analysis of normal colon epithelium and colon adenocarcinoma

Project description:Genome-wide DNA methylation profiles were obtained from colon adenocarcinoma samples (22), corresponding normal colon tissue (22) and cancer-unrelated normal colon tissue using Illumina HumanMethylation450 BeadChips. Approximately 485000 CpG sites were measured in every sample.

2012-12-06 | GSE42752 | GEO

Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer

Project description:We used Illumina Infinium 27k Human DNA Methylation BeadChip v1.2 to assess genome-wide DNA methylation profiling of normal colon epithelial, adenomas and colorectal adenocarcinomas across approximately 27,000 CpGs in fresh frozen colorectal tissue samples. We found that cancer-associated methylation changes with impact on transcription occur nearly as frequent at non-CpG island as CpG island promoters in colorectal cancer (CRC). Samples included 6 normal colon epithelial tissue samples, 6 adenomas, and 30 colorectal adenocarcinomas. Bisulfite-converted DNA from the 42 samples were hybridised to the Illumina Infinium 27k Human Methylation Beadchip v1.2.

2013-06-15 | E-GEOD-40055 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data